IBI-70090

IBI-70090 is a preclinical-stage ophthalmic drug candidate developed by Icon Bioscience (now part of EyePoint Pharmaceuticals) utilizing the proprietary Verisome drug delivery technology. The Verisome platform consists of a liquid-to-gel system that allows for the sustained release of active pharmaceutical ingredients via a single intravitreal or subconjunctival injection. IBI-70090 was specifically being investigated for the treatment of uveitis and dry age-related macular degeneration (dry AMD). Following the acquisition of Icon Bioscience by pSivida (which subsequently rebranded as EyePoint Pharmaceuticals), the development status of this specific program under the IBI-70090 designation has become less clear, as the company shifted focus to other Verisome-based products like DEXYCU and EYP-1901. The specific active ingredient for IBI-70090 has not been publicly disclosed.